AMLX

Company Overview — What Does Amylyx Pharmaceuticals, Inc. Do?

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Amylyx Pharmaceuticals, Inc. (AMLX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joshua B. Cohen and employs approximately 200 people. With a market capitalization of $1.6B, AMLX is one of the notable companies in the Healthcare sector.

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Rating — Hold (April 2026)

As of April 2026, Amylyx Pharmaceuticals, Inc. receives a Hold rating with a composite score of 35.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AMLX ranks #1,569 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Amylyx Pharmaceuticals, Inc. ranks #138 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AMLX Stock Price and 52-Week Range

Amylyx Pharmaceuticals, Inc. (AMLX) currently trades at $16.15. The stock lost $1.17 (6.8%) in the most recent trading session. The 52-week high for AMLX is $17.49, which means the stock is currently trading -7.7% from its annual peak. The 52-week low is $3.11, putting the stock 419.3% above its annual trough. Recent trading volume was 851K shares, suggesting relatively thin trading activity.

Is AMLX Overvalued or Undervalued? — Valuation Analysis

Amylyx Pharmaceuticals, Inc. (AMLX) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.89x, versus the sector average of 2.75x. The price-to-sales ratio is 4323.16x, compared to 1.66x for the average Healthcare stock.

At current multiples, Amylyx Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Amylyx Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Amylyx Pharmaceuticals, Inc. (AMLX) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -60.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -55.5% versus the sector average of -33.1%.

On a margin basis, Amylyx Pharmaceuticals, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -18187.7% (sector: -66.1%). Net profit margin stands at -17476.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AMLX Debt, Balance Sheet, and Financial Health

Amylyx Pharmaceuticals, Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.27x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $225M.

AMLX has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Amylyx Pharmaceuticals, Inc. is 43/100, reflecting average volatility within the normal range for its sector.

Amylyx Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Amylyx Pharmaceuticals, Inc. reported revenue of $416,000 and earnings per share (EPS) of $-1.53. Net income for the quarter was $-184M. Gross margin was 100.0%. Operating income came in at $-192M.

In FY 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.53. Net income for the quarter was $-145M. Operating income came in at $-153M.

In Q3 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.37. Net income for the quarter was $-34M. Operating income came in at $-36M.

In Q2 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.46. Net income for the quarter was $-41M. Operating income came in at $-43M.

Over the past 8 quarters, Amylyx Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $-1M to $416,000. Investors analyzing AMLX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AMLX Dividend Yield and Income Analysis

Amylyx Pharmaceuticals, Inc. (AMLX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AMLX Momentum and Technical Analysis Profile

Amylyx Pharmaceuticals, Inc. (AMLX) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AMLX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Amylyx Pharmaceuticals, Inc. (AMLX) ranks #138 out of 838 stocks based on the Blank Capital composite score. This places AMLX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AMLX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AMLX vs S&P 500 (SPY) comparison to assess how Amylyx Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

AMLX Next Earnings Date

No upcoming earnings date has been announced for Amylyx Pharmaceuticals, Inc. (AMLX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AMLX? — Investment Thesis Summary

Amylyx Pharmaceuticals, Inc. presents a balanced picture with arguments on both sides. The quality score of 22/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers.

In summary, Amylyx Pharmaceuticals, Inc. (AMLX) earns a Hold rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AMLX stock.

Related Resources for AMLX Investors

Explore more research and tools: AMLX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AMLX head-to-head with peers: AMLX vs AZN, AMLX vs SLGL, AMLX vs VMD.